Related Experiment Video
Updated: Sep 8, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Anticancer therapy with novel tubulin-interacting drugs
M Kavallaris1, N M Verrills, B T Hill
1Children's Cancer Institute for Medical Research, Randwick, NSW, Australia. m.kavallaris@unsw.edu.au
Abstract:
Antimitotic agents that target tubulin, including the taxanes and vinca alkaloids, are important components of current anticancer therapy. Whilst these antimitotic drugs are highly effective in the treatment of a number of cancers, both acquired and intrinsic resistance to these agents is a major clinical problem. Furthermore, the systemic toxicity, and in some cases lack of oral availability, make these agents less than ideal. Recently much effort has been directed on the isolation and synthesis of new antimitotic drugs that target the tubulin/microtubule system and display efficacy against drug-refractory carcinomas. Newly described compounds include structurally diverse natural products, such as dolastatin, epothilones and discodermolide, derivatives and structural analogues of traditional antimitotics, and novel synthetic molecules. Additionally, new developments in drug targeting are improving efficacy and therapeutic indices of traditional agents. A number of promising 'new generation' antimitotics are now undergoing clinical testing. These new agents are reviewed here in terms of their mechanism(s) of action on microtubules, effectiveness against drug-resistant tumour cells and clinical potential.
Insights
New antimitotic drugs targeting tubulin show promise against resistant cancers. These agents offer improved efficacy and reduced toxicity compared to traditional therapies.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Antimitotic drugs like taxanes and vinca alkaloids are crucial in cancer treatment.
- Drug resistance and systemic toxicity limit the effectiveness of current antimitotics.
- There is a need for novel antimitotic agents with improved efficacy and safety profiles.
Purpose of the Study:
- To review new antimitotic drugs targeting the tubulin/microtubule system.
- To evaluate their efficacy against drug-resistant cancers.
- To assess their clinical potential and mechanisms of action.
Main Methods:
- Review of recent literature on novel antimitotic compounds.
- Analysis of mechanisms of action on microtubules.
- Evaluation of effectiveness against drug-resistant tumor cells.
Main Results:
- Identification of diverse new compounds including natural products (dolastatin, epothilones) and synthetic molecules.
- Demonstration of efficacy against drug-refractory carcinomas.
- Advancements in drug targeting improving therapeutic indices of existing agents.
Conclusions:
- New generation antimitotics targeting tubulin are under clinical investigation.
- These agents exhibit potential for overcoming resistance and reducing toxicity.
- Further clinical evaluation is warranted to establish their therapeutic value.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy